DFTX · NASDAQ · STOCK
Definium Therapeutics, Inc.
$40.91
52W $12.88 – $49.20
62/100
$5.43B
-11.9
2.24
Is DFTX Bullish or Bearish?
Bullish.
Innellis AI committee rates Definium Therapeutics, Inc. (DFTX) Buy with a composite score of 62/100
, based on 5 analysts with 60% agreement.
Last updated August 11, 2026.
What Would Change This View
- Upgrade to Strong Buy
- Requires a committee score of 75.0 — +13.25 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Watch
- Requires the score to fall below 55.0 — -6.75 from today. The band boundary is 60.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
Positive signals support the current rating — low leverage (debt-to-equity 0.12) -- balance sheet can absorb a shock. The committee sees sufficient evidence to maintain the constructive view.
Bull & Bear Case
Bull Case
- Price structure making higher highs and higher lows — Technical
- Weekly trend (uptrend) confirms the daily trend -- multi-timeframe agreement — Technical
- Low leverage (debt-to-equity 0.12) -- balance sheet can absorb a shock — Risk
- VIX regime is low -- calm backdrop supports risk-taking — Macro
- Market regime is bullish (Bull market -- normal position sizing) — Macro
- Beta of 2.24 means this name should amplify a favorable market regime — Macro
Bear Case
- Price-to-book of 4.0x prices in significant intangible value — Value
- ROE of only -85.2% -- cheap may mean cheap for a reason — Value
- MACD histogram negative -- bearish momentum — Technical
- News sentiment is negative (-0.33 across 3 articles, 14d) — News
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of August 11, 2026
Overall Committee Score
62/100
Agreement
60%
Analysts
5
Conviction
Moderate
Sector Rank
Top 34%
of 192 Healthcare peers
Value Analyst
neutral
43
/ 100 · Moderate confidence
Fair value -- neither a bargain nor obviously overpriced
− Price-to-book of 4.0x prices in significant intangible value
Technical Analyst
bullish
61
/ 100 · High confidence
Price action is constructive -- trend and momentum agree
+ Price structure making higher highs and higher lows
− MACD histogram negative -- bearish momentum
Risk Analyst
bullish
80
/ 100 · Low confidence
Risk profile is manageable -- leverage, volatility, and event exposure all look contained
+ Low leverage (debt-to-equity 0.12) -- balance sheet can absorb a shock
Macro Analyst
bullish
78
/ 100 · Moderate confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
+ VIX regime is low -- calm backdrop supports risk-taking
News Analyst
neutral
47
/ 100 · Low confidence
News flow is mixed or quiet -- no strong signal either way right now
− News sentiment is negative (-0.33 across 3 articles, 14d)
Portfolio Manager
neutral
55
/ 100 · Moderate confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− 2 existing position pair(s) are highly correlated already
Technical Analysis
RSI (14)
36.3
Neutral
MACD Histogram
-0.488
Bearish Momentum
Trend Direction
Uptrend
Weekly: Uptrend
Market Structure
Mixed
Support
$19.34
Resistance
$49.16
Bollinger %B
0.04
Inside Bands
Price vs Moving Averages
EMA 9
$43.72
Below
EMA 21
$43.14
Below
EMA 50
$38.75
Above
EMA 200
$25.31
Above
Fundamental Analysis
Valuation
82
Profitability
0
Financial Health
100
Cash Flow
15
Valuation
P/E Ratio
-11.9×
P/B Ratio
4.93×
PEG Ratio
0.16
Dividend Yield
0.00%
52W High
$49.20
52W Low
$12.88
Quality & Growth
ROE
-5530.5%
ROA
-4176.2%
Gross Margin
0.0%
Operating Margin
0.0%
Revenue Growth YoY
—
Debt / Equity
0.04
AI Fundamental Assessment
[reduced confidence: limited earnings history] P/E ratio of -11.9 (inexpensive relative to a 15-40x range); Price-to-book of 4.9x; PEG ratio of 0.2 (under 1.0 suggests growth is undervalued relative to price); Return on equity of -55.3%; Return on assets of -41.8%; Net margin of 0.0%; Gross margin of 0.0%; Current ratio of 6.95 (healthy short-term liquidity); Debt-to-equity of 0.04; Free cash flow per share is negative (-1.51); Earnings-history trend unavailable; growth based on TTM year-over-year only.
Get the Full DFTX Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →